Anticuerpo monoclonal radiomarcado con 177Lu HuJ591 (177Lu-J591) y ketoconazol en pacientes con cáncer de próstata
Un ensayo aleatorizado de fase 2 del anticuerpo monoclonal radiomarcado con 177Lu HuJ591 (177Lu-J591) y ketoconazol en pacientes con cáncer de próstata en recaída bioquímicamente castrado de alto riesgo después de la terapia local
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This research is being done because the standard treatments for prostate cancer that has returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal therapy are not curative. Existing treatments, such as the ketoconazole used as part of this study may decrease PSA temporarily, but unfortunately the cancer continues to grow. This experimental drug is designed to seek out all of the prostate cancer cells and to deliver a lethal dose of radiation to the areas of cancer, but not to normal areas. Some of the normal organs (liver, kidney and bone marrow) do receive some radiation dose that is within the acceptable limits.
The experimental drug in this study includes an antibody (abbreviated: mAb) called "J591". It is a protein molecule which can bind to a specific site on a prostate cancer cell. A very energetic radioactive (an unstable atom) metal called 177Lutetium (abbreviated: 177Lu) is attached to the J591 antibody. The fully assembled drug is called "177Lu-J591". The study will assess the potential of the energy given off by the radioactive compound to kill cancer cell. This study may also involve the use of 111Indium (abbreviated 111In). This is also an energetic radioactive particle, but does not generally give off enough energy to kill cancer cells, but allows researchers to take pictures. This radioactive particle is also attached to the J591 antibody (called 111In-J591) and will serve as a placebo (treatment with no active medicine).
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Cedars Sinai
-
Los Angeles, California, Estados Unidos, 90089
- USC/Norris Comprehensive cancer center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Georgetown University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood, Kansas, Estados Unidos, 66205
- The University of Kansas Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- XCancer Omaha
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Weill Cornell Medical College
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- University of Utah
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.
-
Biochemical progression (rising PSA) after medical or surgical castration
-
High risk of systemic progression defined as:
- Rising PSA as defined above and either:
- Absolute PSA > 20 ng/mL AND/OR
- PSA doubling time < 8 months
-
No evidence of local recurrence or distant metastases
-
Age >18 years.
-
Serum testosterone < 50 ng/ml
-
Patients capable of fathering children must agree to use an effective method of contraception for the duration of the trial.
-
Subjects on bisphosphonate therapy must be on a stable dose and must have started therapy > 4 weeks prior to protocol therapy.
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
Use of red blood cell or platelet transfusions within 4 weeks of treatment
-
Use of hematopoietic growth factors within 4 weeks of treatment
-
Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment
-
Prior radiation therapy encompassing >25% of skeleton (see Appendix C)
-
Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®)
-
Platelet count <150,000/mm3 or known primary qualitative platelet disorder
-
Absolute neutrophil count (ANC) <2,000/mm3
-
Hematocrit <30 percent and Hemoglobin < 10 g/dL
-
Abnormal coagulation profile (PT or INR, PTT > 1.3x ULN) unless on therapeutic anticoagulation - see concomitant meds section
-
Serum creatinine >2.5 mg/dL
-
AST (SGOT) >2x ULN
-
Bilirubin (total) >1.5x ULN; subjects with Gilbert's syndrome will be allowed if direct bilirubin is within institutional normal limits
-
Active serious infection
-
Active angina pectoris or NY Heart Association Class III-IV
-
ECOG Performance Status > 2
-
Life expectancy <12 months
-
History of deep vein thrombosis and/or pulmonary embolus within 1 month of study entry
-
Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
-
Prior investigational therapy (medications or devices) within 4 weeks of treatment. Furthermore, other investigational therapy is not permitted during the treatment phase.
-
Prior use of ketoconazole for the purposes of prostate cancer therapy for greater than 1 month
-
Known history of HIV. The effects of J591 are unknown in this population. Furthermore, ketoconazole has many well-described drug-drug interactions which could affect antiviral therapy. If necessary, this population will be studied separately.
-
Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have "currently active" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.
- Known history of known myelodysplastic syndrome
-
Adrenal hormone inhibitors (other than ketoconazole) within 4 weeks prior to study enrollment
-
Finasteride (Propecia® or Proscar®) or dutasteride (Avodart®) within 4 weeks of enrollment
-
Patients on corticosteroids prior to enrollment must have either discontinued and shown biochemical progression or have biochemical progression on a stable dose
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 1. 177Lu-J591 + Ketoconazole
Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone |
177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
Otros nombres:
Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
Otros nombres:
Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
Otros nombres:
|
|
Comparador de placebos: 2. 111In-J591 + Ketoconazole
Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone |
Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
Otros nombres:
Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
Otros nombres:
111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants Free of Radiographically Evident Metastases From Baseline to 18 Months After Study Drug Administration
Periodo de tiempo: Baseline and 18 months after study drug administration
|
Subjects will perform a CT and/or MRI scan of the abdomen and pelvis, chest x-ray or CT scan of the chest and bone scan to determine the proportion of participants free of radiographically evident metastases from baseline to 18 months after study drug administration. |
Baseline and 18 months after study drug administration
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in PSA Response Rate
Periodo de tiempo: Collected at screening, V2, V3, V5, V9 then every 4 weeks till PSA progression or end of study at approximately 100 months
|
PSA response will be determined by comparing the PSA levels after therapy to the baseline and pre-treatment PSA via blood specimens |
Collected at screening, V2, V3, V5, V9 then every 4 weeks till PSA progression or end of study at approximately 100 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Scott T Tagawa, M.D., Weill Medical College of Cornell University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos policíclicos
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Embarazadas
- Embarazo
- 11-hidroxicorticosteroides
- Hidroxicorticosteroides
- Hormonas de la corteza suprarrenal
- 17-hidroxicorticosteroides
- Piperazines
- Hidrocortisona
- Ketoconazol
- Anticuerpo monoclonal J591
Otros números de identificación del estudio
- 0810010067
- J591+Ketoconazole (Otro identificador: Weill Cornell Medicine)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .